Back to Search
Start Over
Ribavirin for Hepatitis E Virus Infection After Organ Transplantation
- Source :
- Clinical Infectious Diseases, Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(5), 1204-1211. Oxford University Press, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, United States, Clinical Infectious Diseases, 71(5), 1204-1211. Oxford University Press, Clinical Infectious Diseases, Oxford University Press (OUP), 2019, ⟨10.1093/cid/ciz953⟩, Clinical Infectious Diseases, 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response. Methods Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29–1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25–18) months. Results After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event. Conclusions This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance. This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.
- Subjects :
- 0301 basic medicine
MESH: Antiviral Agents / therapeutic use
Sofosbuvir
viruses
medicine.disease_cause
Gastroenterology
THERAPY
Organ transplantation
Hepatitis E virus / genetics
Hepatitis E / drug therapy
Humans
chemistry.chemical_compound
0302 clinical medicine
Hepatitis E virus
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Medicine
MUTATION
MESH: Hepatitis E* / drug therapy
POLYMERASE
organ transplantation
virus diseases
MESH: Ribavirin / therapeutic use
Anemia
[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences
Hepatitis E
anemia
3. Good health
PREDICTS
Sustained virological response
Infectious Diseases
MESH: RNA, Viral
[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
RNA, Viral
030211 gastroenterology & hepatology
sustained virological response
medicine.drug
Microbiology (medical)
medicine.medical_specialty
ribavirin
MESH: Organ Transplantation / adverse effects
RNA, Viral Retrospective Studies
Ribavirin / therapeutic use
Alpha interferon
MESH: Organ Transplantation* / adverse effects
hepatitis E virus
Antiviral Agents
Virus
03 medical and health sciences
SDG 3 - Good Health and Well-being
Internal medicine
Ribavirin
Retrospective Studies
MESH: Hepatitis E virus* / genetics
MESH: Humans
business.industry
Retrospective cohort study
MESH: Retrospective Studies
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
IN-VITRO
medicine.disease
digestive system diseases
030104 developmental biology
chemistry
SOFOSBUVIR
HEV
REPLICATION
INTERFERON-ALPHA
business
Subjects
Details
- Language :
- English
- ISSN :
- 10584838 and 15376591
- Database :
- OpenAIRE
- Journal :
- Clinical Infectious Diseases, Clinical Infectious Diseases, Oxford University Press (OUP), 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(5), 1204-1211. Oxford University Press, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, United States, Clinical Infectious Diseases, 71(5), 1204-1211. Oxford University Press, Clinical Infectious Diseases, Oxford University Press (OUP), 2019, ⟨10.1093/cid/ciz953⟩, Clinical Infectious Diseases, 2020, 71 (5), pp.1204-1211. ⟨10.1093/cid/ciz953⟩
- Accession number :
- edsair.doi.dedup.....9291b965e91f3ecf369fd895a0047810